Oscar Cuzzani, MD, PhD, VP of clinical development, detailed the company’s two ophthalmology programs including cell replacement that could be used to treat dry AMD. BioTime’s OpRegen could be injected into the eye to repair the damaged retina. Dr. Cuzzani presented some results from animal studies. The company now is conducting a Phase I/IIa study to further test the retinal replacement. The study will involved 15 patients at five study sites, three in Israel and two still to be identified in the US.